At the same time, in vivo experimental results showed that under the action of activated human T cells, AMG 330 targeting CD33 could inhibit the growth of xenografts of humanized mouse subcutaneous AML cell lines, thereby significantly improving the survival rate (76, 77). The gene discussed is CD33; the disease is acute myeloid leukemia.